Center for Disease Analysis

Recent papers from Center for Disease Analysis

1. Modelling the impact of physical activity on MASLD in Saudi ArabiaPLoS ONE · 2026
2. Risk of Liver Cancer From Major Causes Compared to Smoking and Lung Cancer: A Systematic Review and Meta‐AnalysisJournal of Viral Hepatitis · 2026
3. Prevention of HBV Mother‐To‐Child Transmission ( MTCT ) Using Targeted HBV Birth Dose, and Treatment of High Viral Load Pregnant Women in UgandaJournal of Viral Hepatitis · 2026
4. Development and Preclinical Evaluation of a Novel EpCAM-Targeted ¹¹¹ In-Labeled Antibody for SPECT ImagingACS Omega · 2026
5. From Targets to Real World Impact: A Review of Models of Care for Chronic HBV and HCV in EuropeThe Lancet Regional Health - Europe · 2026
6. C102-06 Initial Evaluation of Acceptability, Engagement, and Effectiveness of the MoTm Smartphone App to Provide Comprehensive Support for Smoking Cessation: Development and Usability StudyAmerican Journal of Respiratory and Critical Care Medicine · 2026
7. Implementing sustainable liver health in Europe: a second EASL–Lancet CommissionThe Lancet · 2026
8. Toward Rapid Actinium-225 Purification via Membrane Adsorbers with Covalently Tethered Diglycolamide LigandsACS Applied Materials & Interfaces · 2026
9. The Current Burden of Hepatitis B in the United States: A State, Territorial, and County Modelling AnalysisJournal of Viral Hepatitis · 2025
10. Financial risk protection from vaccines in 52 Gavi-eligible low- and middle-income countries: A modeling studyPLoS Medicine · 2025
11. Closing the gap in HCV care: strategic collaboration between industry, academic, community, and nonprofit researchersnpj gut and liver. · 2025
12. Estimating the impact of displacement from Ukraine on HBV and HCV prevalence among migrants in the European Union, 2024: a modeling studyThe Lancet Regional Health - Europe · 2025
13. A call to reclassify the delta hepatitis virus as an orphan diseaseHepatology Communications · 2025
14. Prioritising viral hepatitis elimination to prevent hepatocellular carcinoma: A public health approach for effective preventive hepatologyJHEP Reports · 2025
15. Addressing the High and Rising Global Burden of Metabolic Dysfunction‐Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction‐Associated Steatohepatitis (MASH): From the Growing Prevalence to Payors' PerspectiveAlimentary Pharmacology & Therapeutics · 2025
16. Number of people treated for hepatitis C virus infection in 2014-2023 and applicable lessons for new HBV and HDV therapiesTyöväentutkimus Vuosikirja · 2025
17. Modeling the health and economic impact of pharmacologic therapies for MASLD in the United StatesJournal of Hepatology · 2025
18. The economic argument for hepatitis B treatment simplification and expansionJournal of Viral Hepatitis · 2024
19. Hepatitis C screening in Lithuania: first-year results and scenarios for achieving WHO elimination targetsBMC Public Health · 2024
20. Global HBV disease burden and current care gapsClinical Liver Disease · 2024